Emerging studies suggest Retatrutide , a dual activator targeting both GLP-1 and GIP , appears to represent a notable step forward for body loss . Early clinical trials have shown substantial reductions in visceral mass , possibly exceeding current weight-loss treatments. Nevertheless , additional assessment is necessary to thoroughly determine its